Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/16/2017 02/17/2017 02/21/2017 02/22/2017 02/23/2017 Date
47.02(c) 48.28(c) 46.86(c) 45.95(c) 46.3 Last
870 124 799 181 728 226 632 121 310 904 Volume
-0.15% +2.68% -2.94% -1.94% +0.76% Change
More quotes
Financials ($)
Sales 2017 73,2 M
EBIT 2017 -453 M
Net income 2017 -442 M
Finance 2017 550 M
Yield 2017 -
Sales 2018 146 M
EBIT 2018 -423 M
Net income 2018 -420 M
Finance 2018 322 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 46,5x
EV / Sales2018 24,8x
Capitalization 3 952 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.The... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
02/16 ALNYLAM PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2016 Financial Re..
02/16 ALNYLAM PHARMACEUTICALS : Presents New Data on Fitusiran at EAHAD
02/15 ALNYLAM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
02/10 ALNYLAM PHARMACEUTICALS, INC. : Reports Inducement Grant Under NASDAQ Listing Ru..
02/08 ALNYLAM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, F..
02/08 ALNYLAM PHARMACEUTICALS : reports 4Q loss
02/08 ALNYLAM PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2016 Financial Re..
02/02 ALNYLAM PHARMACEUTICALS : Presents New Data on Fitusiran at EAHAD
02/01 ALNYLAM PHARMACEUTICALS : to Webcast Conference Call Discussing Fourth Quarter a..
01/21 INSIDER TRADING ACTIVITY ALNYLAM PHA : ALNY) – Director Sold 15,000 shares..
More news
Sector news : Biotechnology & Medical Research - NEC
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07:00pDicerna CEO Talks Goals For 2017, Competitors And Prospects Under Trump  
06:11aAlnylam Pharmaceuticals upgraded by Vetr Inc. to strong-buy. $52.94 PT.  
02/22Exclusive: Dicern CEO Talks Goals For 2017, Competitors And Prospects Under T.. 
02/16Industry Leaders: Relaxing FDA Standards Will Kill The Pharma Golden Goose  
02/16Biotech stocks that didn't get hit with that first press lower: $ALNY $SAGE .. 
More tweets
Qtime:23
News from SeekingAlpha
02/16 INDUSTRY LEADERS : Relaxing FDA Standards Will Kill The Pharma Golden Goose
02/09 Alnylam Pharmaceuticals, Inc. 2016 Q4 - Results - Earnings Call Slides
02/09 Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2016 Results - Earn..
02/08 Alnylam collaboration revenue up 131%; net loss widens; quick assets down 26%
02/08 Alnylam Pharmaceuticals beats by $0.02, beats on revenue
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 62,7 $
Spread / Average Target 37%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne Greenstreet Chief Operating Officer & Executive Vice President
Michael P. Mason Treasurer, Chief Financial & Accounting Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICAL..25.16%3 952
INCYTE CORPORATION22.03%22 987
QUINTILES IMS HOLDINGS..0.26%18 233
CELLTRION, INC.--.--%10 892
LONZA GROUP AG2.67%10 437
SEATTLE GENETICS, INC.24.46%9 141
More Results